TEM Tempus AI Inc
$65.50
▼ 7.9%Updated Oct 16, 2:25 PM ET
Report Card
TEM at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.
Key Metrics
Market Cap
—
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-45.0%
Interest Coverage
—
Current Ratio
3.3x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
Not rated
Business Overview
Tempus AI Inc (TEM) is a NASDAQ-listed company in the Life Sciences Tools & Services industry, within the Health Care sector.
In its latest reported year it generated about $1.27B in revenue and posted a net loss of $245.03M.
Our model hasn't rated TEM yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.
Revenue Growth
3Y CAGR
58.3%
Revenue moved from $320.67M in 2022 to $1.27B in 2025, a 58.3% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
—
Operating Margin
-19.9%
Net Margin
-19.3%
ROE
—
Debt Analysis
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 3.3x. Detailed balance-sheet leverage is limited for this name.
Cash Flow Analysis
Operating CF
-$218.09M
Free Cash Flow
-$239.14M
FCF Margin
-18.8%
In the latest year Tempus AI Inc produced about -$218.09M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Dividend Safety
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
What to look for in a dividend stockCoverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Total paid (latest FY)
$5.63M
History on record
3 years
free cash flow was negative in the latest year — the dividend is being financed
no current raise streak
no cuts in the last 3 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
Valuation Analysis
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
TEM trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.
Metrics vs. Sector Range
Where TEM sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How TEM stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
TEM doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.
P/E vs sector
—
median 26.1x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
—
not rated yet
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Analyst Ratings
What 23 Wall Street analysts covering TEM recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-4 pts of buy ratings).
Latest SEC Filings
TEM's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
TEM — frequently asked questions
Is TEM a good stock to buy?
We don't give buy or sell advice. Review Tempus AI Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does TEM's data come from?
Live price data plus the annual financials in Tempus AI Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.
How is the 5-year projection for TEM calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this TEM analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell TEM. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.